STOCK TITAN
  1. Home
  2. News
  3. PCSA

Processa Pharmaceuticals Inc - PCSA STOCK NEWS

Welcome to our dedicated news page for Processa Pharmaceuticals (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Processa Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Processa Pharmaceuticals's position in the market.

News
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
Rhea-AI Summary
Processa Pharmaceuticals, Inc. announces a reverse stock split to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market. The reverse stock split will reduce the number of outstanding common stock shares from approximately 24.6 million shares to approximately 1.2 million shares, with a split ratio of 1-for-20. The Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol 'PCSA' with the new CUSIP number 74275C304.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1392.65%
Tags
stock split
-
News
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces CEO George Ng's corporate overview presentation at the Biotech Showcase 2024, focusing on developing next-gen chemotherapeutic drugs for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences
-
News
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) provides interim analysis from its Phase 1b study of Next Generation Capecitabine (NGC-Cap), showing improved safety and efficacy over capecitabine. Patients received lower doses of NGC-Cap resulting in 5-FU exposure up to 10 times greater than capecitabine, with similar side effect profiles. FDA confirms NGC-Cap as a new chemical entity, suggesting higher efficacy and better safety profile. Fireside Chat on December 20, 2023, to discuss the data and corporate strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.36%
Tags
clinical trial
News
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces positive outcomes from a meeting with the FDA regarding the next Phase 2 study for Next Generation Capecitabine ('NGC-Cap') for cancer patients. The FDA provided helpful guidance on the study design and dosage regimen, based on positive interim results from the ongoing Phase 1b study. Processa anticipates beginning enrollment for the Phase 2 study in mid-2024, aiming to provide a better safety/efficacy profile for patients who cannot tolerate existing Capecitabine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.4%
Tags
clinical trial
-
News
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces Dr. David Young, President of Research and Development, will present at the MedInvest Oncology Investor Conference. Processa CEO George Ng will be available for one-on-one meetings with investors at the conference venue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.53%
Tags
conferences
-
News
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for cancer patients. CEO George Ng recently issued a letter to shareholders, emphasizing the company's pivot to focus on oncology drug product development and the potential for safer and more effective chemotherapy treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18%
Tags
none
News
Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces the unexpected passing of Director Virgil Thompson at 83. Mr. Thompson served on the Board of Directors since 2017 and was previously on the Board of Directors of Promet Therapeutics, LLC. The company expresses great sadness and gratitude for his leadership and wisdom.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.77%
Tags
management
-
News
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces Dr. David Young, President of Research and Development, will present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas. The conference is on November 16 – 17, 2023, at the Revere Hotel Boston Common. Dr. Young will be available for one-on-one meetings throughout the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
conferences
-
News
Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders
Rhea-AI Summary
Processa Pharmaceuticals announces the formation of its Oncology Advisory Board to assist in the design of oncology trial protocols, including the anticipated Phase 2 trial for NGC-Cap. The board comprises key opinion leaders from renowned institutions. Processa aims to develop next-generation chemotherapeutic drugs to enhance cancer treatment efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
management
News
Processa Pharmaceuticals to Present at the ThinkEquity Conference
Rhea-AI Summary
Processa Pharmaceuticals to present updated corporate overview at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.45%
Tags
conferences
Stock PCSA logo
Processa Pharmaceuticals Inc

Nasdaq:PCSA

PCSA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PCSA Stock Data

4.77M
2.49M
11.27%
1.98%
1.25%
Heavy Duty Truck Manufacturing
Manufacturing
Link
United States
Hanover

About PCSA

processa pharmaceuticals was founded in october 2017 with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. the company is headquartered in hanover, maryland.